Australian & New Zealand Journal of Psychiatry
April 16, 2024
Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al.
9 citations
The Australian government's recent rescheduling of psilocybin and MDMA for limited clinical use has raised regulatory challenges for psychedelic-assisted therapy. Through a desktop review, interviews with experts, and framework analysis, researchers developed a taxonomy of regulatory matters across six domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—contain many matters with uncertainty or conflicting views, such as where services should be located and which professionals qualify as therapists. The remaining domains—Patient Evaluation, Drug Supply, and Service Oversight—are relatively settled, with established regulation or consensus that regulation is unnecessary. The taxonomy offers a roadmap for health services and policymakers.
JAMA network open
July 1, 2025
Sarah-Catherine Rodan, Sarah Maguire, Noah Meez et al.
5 citations
In a large international survey of over 6,600 adults with eating disorders or disordered eating, cannabis and psychedelics were rated as most helpful for improving eating disorder symptoms, while prescription antidepressants were seen as beneficial for overall mental health but not for eating disorder symptoms, except for fluoxetine in bulimia nervosa and lisdexamfetamine in binge-eating disorder. Alcohol, nicotine, and tobacco were rated as most harmful. The findings suggest that cannabis and psychedelics may alleviate eating disorder symptoms, supporting further research into these substances as potential treatments.
Journal of eating disorders
July 24, 2025
Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al.
2 citations
Among adults with eating disorders, about one in three reported having used a psychedelic drug at some point, and one in five had used one in the past year. Users tended to be younger, less likely to take prescription drugs or be hospitalized for their eating disorder, and more likely to use other non-prescription drugs and to have ADHD, PTSD, ASD, or substance misuse. Those with anorexia nervosa were less likely to report psychedelic use, while those with an undiagnosed eating disorder were more likely. Qualitative comments described profound transformation, increased connectedness, and new insights into illness, though a few reported bad trips or worsened symptoms. The findings suggest psychedelics may hold promise for this population and warrant clinical trials.